Phosphagenics Announce Positive Phase 1 Clinical Trial Results for Transdermal Lidocaine
News Dec 11, 2008
Phosphagenics Limited has announced the successful completion of a phase 1 clinical trial that examined the ability of its patented drug delivery system, TPM, to topically deliver the pain relief drug, lidocaine, safely into humans.
The trial demonstrated that the patented lidocaine formulation was able to deliver a greater amount of lidocaine into the localized area of the skin compared to a leading commercial product, Phosphagenics explains.
Lidocaine is a well known topical anaesthetic, sales of which exceeded US $1.2 billion in 2007. It is used for a wide variety of ailments, including temporary relief of rashes, stings, sprains, strains, bites, and burns.
This clinical trial compared the dermal penetration and measured the systemic exposure of lidocaine between one of the leading marketed products, Xylocaine® (5% lidocaine), and Phosphagenics’ TPM/lidocaine (5% lidocaine).
Dr Esra Ogru, Executive Vice President of Research and Development at Phosphagenics said; “While we have previously demonstrated the penetrative power of our TPM technology, the success of this trial validates the versatility and precision of Phosphagenics’ drug delivery platform in humans. We view this as a major achievement for our company and look forward to moving ahead with further clinical trials.”
The open label, single centre study was conducted at the Centre for Pharmaceutical Research, University of South Australia, under the guidance of Principal Investigator Dr. David Foster. 11 healthy adult volunteers enrolled in the bioavailability trial of dermal and systemic pharmacokinetics, which incorporated secondary endpoints of safety and tolerability.
8th Edition of International Conference and Exhibition on Separation Techniques
Jul 29 - Jul 30, 2019
International Women Health and Breast Cancer Conference
Jul 03 - Jul 05, 2019
2nd International Conference on Biological & Pharmaceutical Sciences
Jul 12 - Jul 13, 2019
2nd International Conference on Computational Biology and Bioinformatics
May 17 - May 18, 2019